^
Association details:
| Biomarker: | PAN3-PSMA2 fusion |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | decitabine (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PAN3- PSMA2 fusion resulting from a novel t(7;13)(p14;q12) chromosome translocation in a myelodysplastic syndrome that evolved into acute myeloid leukemia
Excerpt:
The novel t(7;13)(p14;q12)/PAN3-PSMA2 in the neoplastic bone marrow cells could affect two key protein complex: (a) the PAN2/PAN3 complex (PAN3 rearrangement)....The patient showed a favorable response to decitabine after treatment with 5-azacitidine and conventional intensive chemotherapy had failed. Whether this might represent a consistent feature of MDS/AML with this particular gene fusion, remains unknown.
DOI:
10.1186/s40164-018-0099-4
